Base de dados : MEDLINE
Pesquisa : D02.241.081.844.387 [Categoria DeCS]
Referências encontradas : 973 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 98 ir para página                         

  1 / 973 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28985563
[Au] Autor:Faubert B; Li KY; Cai L; Hensley CT; Kim J; Zacharias LG; Yang C; Do QN; Doucette S; Burguete D; Li H; Huet G; Yuan Q; Wigal T; Butt Y; Ni M; Torrealba J; Oliver D; Lenkinski RE; Malloy CR; Wachsmann JW; Young JD; Kernstine K; DeBerardinis RJ
[Ad] Endereço:Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA.
[Ti] Título:Lactate Metabolism in Human Lung Tumors.
[So] Source:Cell;171(2):358-371.e9, 2017 Oct 05.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cancer cells consume glucose and secrete lactate in culture. It is unknown whether lactate contributes to energy metabolism in living tumors. We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the tricarboxylic acid (TCA) cycle. Here, we show that lactate is also a TCA cycle carbon source for NSCLC. In human NSCLC, evidence of lactate utilization was most apparent in tumors with high fluorodeoxyglucose uptake and aggressive oncological behavior. Infusing human NSCLC patients with C-lactate revealed extensive labeling of TCA cycle metabolites. In mice, deleting monocarboxylate transporter-1 (MCT1) from tumor cells eliminated lactate-dependent metabolite labeling, confirming tumor-cell-autonomous lactate uptake. Strikingly, directly comparing lactate and glucose metabolism in vivo indicated that lactate's contribution to the TCA cycle predominates. The data indicate that tumors, including bona fide human NSCLC, can use lactate as a fuel in vivo.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/metabolismo
Ácido Láctico/metabolismo
Neoplasias Pulmonares/metabolismo
[Mh] Termos MeSH secundário: Animais
Análise Química do Sangue
Linhagem Celular Tumoral
Ciclo do Ácido Cítrico
Modelos Animais de Doenças
Feminino
Ácidos Glicéricos/metabolismo
Xenoenxertos
Seres Humanos
Masculino
Camundongos
Transportadores de Ácidos Monocarboxílicos/genética
Transportadores de Ácidos Monocarboxílicos/metabolismo
Transplante de Neoplasias
Simportadores/genética
Simportadores/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glyceric Acids); 0 (Monocarboxylic Acid Transporters); 0 (Symporters); 0 (monocarboxylate transport protein 1); 33X04XA5AT (Lactic Acid); 820-11-1 (3-phosphoglycerate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  2 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28805803
[Au] Autor:Oslund RC; Su X; Haugbro M; Kee JM; Esposito M; David Y; Wang B; Ge E; Perlman DH; Kang Y; Muir TW; Rabinowitz JD
[Ad] Endereço:Department of Chemistry, Princeton University, Princeton, New Jersey, USA.
[Ti] Título:Bisphosphoglycerate mutase controls serine pathway flux via 3-phosphoglycerate.
[So] Source:Nat Chem Biol;13(10):1081-1087, 2017 Oct.
[Is] ISSN:1552-4469
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lower glycolysis involves a series of reversible reactions, which interconvert intermediates that also feed anabolic pathways. 3-phosphoglycerate (3-PG) is an abundant lower glycolytic intermediate that feeds serine biosynthesis via the enzyme phosphoglycerate dehydrogenase, which is genomically amplified in several cancers. Phosphoglycerate mutase 1 (PGAM1) catalyzes the isomerization of 3-PG into the downstream glycolytic intermediate 2-phosphoglycerate (2-PG). PGAM1 needs to be histidine phosphorylated to become catalytically active. We show that the primary PGAM1 histidine phosphate donor is 2,3-bisphosphoglycerate (2,3-BPG), which is made from the glycolytic intermediate 1,3-bisphosphoglycerate (1,3-BPG) by bisphosphoglycerate mutase (BPGM). When BPGM is knocked out, 1,3-BPG can directly phosphorylate PGAM1. In this case, PGAM1 phosphorylation and activity are decreased, but nevertheless sufficient to maintain normal glycolytic flux and cellular growth rate. 3-PG, however, accumulates, leading to increased serine synthesis. Thus, one biological function of BPGM is controlling glycolytic intermediate levels and thereby serine biosynthetic flux.
[Mh] Termos MeSH primário: Ácidos Glicéricos/metabolismo
Fosfoglicerato Mutase/metabolismo
Serina/metabolismo
[Mh] Termos MeSH secundário: Seres Humanos
Fosfoglicerato Mutase/deficiência
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glyceric Acids); 452VLY9402 (Serine); 820-11-1 (3-phosphoglycerate); EC 5.4.2.1 (phosphoglycerate mutase 1, human); EC 5.4.2.11 (Phosphoglycerate Mutase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE
[do] DOI:10.1038/nchembio.2453


  3 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28726668
[Au] Autor:Gokadze S; Barbakadze V; Mulkijanyan K; Bakuridze A; Bakuridze L
[Ad] Endereço:Tbilisi State Medical University, Georgia.
[Ti] Título:FORMULATION AND TECHNOLOGY DEVELOPMENT OF HERBAL PHENOLIC BIOPOLYMER-CONTAINING FILMS FOR BURN TREATMENT.
[So] Source:Georgian Med News;(267):119-124, 2017 Jun.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:eng
[Ab] Resumo:Application of phytofilms based on biosolublepolymers is considered as a prospectivemethod for burn treatment . Herbal remedies contain biologically active substances, that are relatively less toxic, do not cause skin irritation or allergic reactions and, importantly, affectstrains of the microorganisms and viruses resistant to antibiotics and synthetic drugs. Nowadays, the advantages are given to such burn healing drugs, which along with high specific efficacy, have analgesic, anti-inflammatory and antimicrobial effects, and don't irritate the tissues. The mentioned peculiarities are characteristic for a new herbal phenolic biopolymer poly[3-(3,4-dihydroxyphenyl) glyceric acid](PDGA), isolated from the roots and stems of different comfrey species . The aim of the study was the development of the formulation and technology of biosoluble films for burn treatment on the basis of PDGA. The optimal content of phytofilm for burn healing was selected on the basis of the biopharmaceutical study results. The impact of the film-former on the quality, adhesion and moisture absorption of the phytofilmhas been studied. The optimal degree of the phytofilm moisture, determining its high adhesive properties,was established. The film prepared on the basis of sodium alginate, with 30.4% humidity, demonstrated the greatest adhesion strength. After investigation of the PDGA release it was found, that the hydrophilic bases such as: sodium carboxymethyl-cellulose (69.2%) andsodium alginate (78,65%) appeared to be optimal among the others. At the same time, taking into consideration the disadvantages of sodium carboxymethyl-cellulose (tautening effect on burnt surface, relatively low stability), a film based on sodium alginate has been chosen. The manufacturing technology for obtaining PDGA-containing phytofilm by casting is proposed. Theshelf-lifeofproposedPDGA-containingphytofilmis 2 years.
[Mh] Termos MeSH primário: Queimaduras/terapia
Confrei/química
Ácidos Glicéricos/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/química
Biopolímeros/química
Raízes de Plantas/química
Caules de Planta/química
Cicatrização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Biopolymers); 0 (Glyceric Acids); 0 (poly(3-(3,4-dihydroxyphenyl)glyceric acid))
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE


  4 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28622455
[Au] Autor:Asquith M; Davin S; Stauffer P; Michell C; Janowitz C; Lin P; Ensign-Lewis J; Kinchen JM; Koop DR; Rosenbaum JT
[Ad] Endereço:Oregon Health and Science University, Portland.
[Ti] Título:Intestinal Metabolites Are Profoundly Altered in the Context of HLA-B27 Expression and Functionally Modulate Disease in a Rat Model of Spondyloarthritis.
[So] Source:Arthritis Rheumatol;69(10):1984-1995, 2017 Oct.
[Is] ISSN:2326-5205
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: HLA-B27-associated spondyloarthritides are associated with an altered intestinal microbiota and bowel inflammation. We undertook this study to identify HLA-B27-dependent changes in both host and microbial metabolites in the HLA-B27/ß -microglobulin (ß m)-transgenic rat and to determine whether microbiota-derived metabolites could impact disease in this major model of spondyloarthritis. METHODS: Cecal contents were collected from Fischer 344 33-3 HLA-B27/ß m-transgenic rats and wild-type controls at 6 weeks (before disease) and 16 weeks (with active bowel inflammation). Metabolomic profiling was performed by high-throughput gas and liquid chromatography-based mass spectrometry. HLA-B27/ß m-transgenic rats were treated with the microbial metabolites propionate or butyrate in drinking water for 10 weeks, and disease activity was subsequently assessed. RESULTS: Our screen identified 582 metabolites, of which more than half were significantly altered by HLA-B27 expression at 16 weeks. Both microbial and host metabolites were altered, with multiple pathways affected, including those for amino acid, carbohydrate, xenobiotic, and medium-chain fatty acid metabolism. Differences were even observed at 6 weeks, with up-regulation of histidine, tyrosine, spermidine, N-acetylmuramate, and glycerate in HLA-B27/ß m-transgenic rats. Administration of the short-chain fatty acid propionate significantly attenuated HLA-B27-associated inflammatory disease, although this was not associated with increased FoxP3+ T cell induction or with altered expression of the immunomodulatory cytokines interleukin-10 (IL-10) or IL-33 or of the tight junction protein zonula occludens 1. HLA-B27 expression was also associated with altered host expression of messenger RNA for the microbial metabolite receptors free fatty acid receptor 2 (FFAR2), FFAR3, and niacin receptor 1. CONCLUSION: HLA-B27 expression profoundly impacts the intestinal metabolome, with changes evident in rats even at age 6 weeks. Critically, we demonstrate that a microbial metabolite, propionate, attenuates development of HLA-B27-associated inflammatory disease. These and other microbiota-derived bioactive mediators may provide novel treatment modalities in HLA-B27-associated spondyloarthritides.
[Mh] Termos MeSH primário: Ceco/metabolismo
Microbioma Gastrointestinal
Antígeno HLA-B27/genética
Espondiloartropatias/metabolismo
[Mh] Termos MeSH secundário: Animais
Ácido Butírico/farmacologia
Ceco/microbiologia
Cromatografia Líquida de Alta Pressão
Modelos Animais de Doenças
Ácidos Graxos Voláteis/metabolismo
Citometria de Fluxo
Cromatografia Gasosa-Espectrometria de Massas
Perfilação da Expressão Gênica
Ácidos Glicéricos/metabolismo
Histidina/metabolismo
Interleucina-10/imunologia
Interleucina-33/imunologia
Linfonodos/citologia
Espectrometria de Massas
Mesentério
Metabolômica
Ácidos Murâmicos/metabolismo
Propionatos/farmacologia
Ratos
Ratos Endogâmicos F344
Ratos Transgênicos
Espermidina/metabolismo
Baço/citologia
Espondiloartropatias/genética
Espondiloartropatias/imunologia
Linfócitos T/imunologia
Tirosina/metabolismo
Regulação para Cima
Microglobulina-2 beta/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fatty Acids, Volatile); 0 (Glyceric Acids); 0 (HLA-B27 Antigen); 0 (Interleukin-33); 0 (Muramic Acids); 0 (Propionates); 0 (beta 2-Microglobulin); 107-92-6 (Butyric Acid); 130068-27-8 (Interleukin-10); 246FXU111L (N-acetylmuramic acid); 42HK56048U (Tyrosine); 4QD397987E (Histidine); 70KH64UX7G (glyceric acid); DK6Y9P42IN (sodium propionate); U87FK77H25 (Spermidine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170617
[St] Status:MEDLINE
[do] DOI:10.1002/art.40183


  5 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28515381
[Au] Autor:Sato S; Kitamoto D; Habe H
[Ad] Endereço:Research Institute for Sustainable Chemistry, National Institute of Advanced Industrial Science and Technology (AIST).
[Ti] Título:Preliminary Evaluation of Glyceric Acid-producing Ability of Acidomonas methanolica NBRC104435 from Glycerol Containing Methanol.
[So] Source:J Oleo Sci;66(6):653-658, 2017 Jun 01.
[Is] ISSN:1347-3352
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Some acetic acid bacteria produce large amounts of glyceric acid (GA) from glycerol in culture broth. However, methanol, which is a major contaminant of raw glycerol derived from the biodiesel fuel industry, sharply decreases cell growth and GA production [AMB Express, 3, 20, 2013]. Thus, we evaluated the methylotrophic acetic acid bacterium Acidomonas methanolica NBRC104435 for its ability to produce GA from glycerol containing methanol. This strain accumulated GA in its culture broth when 1-3 wt% glycerol was available as a carbon source. We observed improved cell growth and GA accumulation when 1 vol% methanol was added to the 3-5 wt% glycerol medium. The maximum concentration of GA was 12.8 g/L in medium containing 3 wt% glycerol plus 1 vol% methanol. In addition, the enantiomeric excess (ee) of the GA produced was revealed to be 44%, indicating that this strain converted glycerol to d-GA with a lower enantioselectivity than other acetic acid bacteria, which had 70-99% ee.
[Mh] Termos MeSH primário: Acetobacteraceae/metabolismo
Ácidos Glicéricos/metabolismo
Glicerol/metabolismo
Metanol/metabolismo
[Mh] Termos MeSH secundário: Acetobacteraceae/crescimento & desenvolvimento
Glicerol/química
Metanol/química
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glyceric Acids); 70KH64UX7G (glyceric acid); PDC6A3C0OX (Glycerol); Y4S76JWI15 (Methanol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.5650/jos.ess16236


  6 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28252436
[Au] Autor:Gokadze S; Barbakadze V; Mulkijanyan K; Bakuridze L; Bakuridze A
[Ad] Endereço:Tbilisi State Medical University, Georgia.
[Ti] Título:DEVELOPMENT OF FORMULATION AND TECHNOLOGY FOR THE POLY[3-(3,4-DIHYDROXYPHENYL)GLYCERIC ACID] GEL.
[So] Source:Georgian Med News;(262):92-98, 2017 Jan.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:eng
[Ab] Resumo:One of the most actual problems of pharmacy is the development of medication forms for external application with complex effects on (gel, emplastro, aerosol, etc.) skin wounds, burns and inflammatory factors. The centuries-old practice of using phyto-preparations (herbal remedies) proved that they have fewer side effects in comparison with synthetic drugs. Despite the wide application of herbal preparations, in the literature there is a little information about their application in development of wound and burn healing modern dosage forms. Among the medicinal plants with the mentioned pharmacological actions, comfrey (Symphytum L.) should be distinguished. Phenolic polymer poly[3-(3,4-dihydroxyphenyl)glyceric acid] (PDGA) or poly[oxy-1-carboxy-2-(3,4-dihydroxyphenyl)ethylene], amounting approximately 25% of polysaccharides and 1.5-2.5% of dry plant material, were isolated from the roots and stems of Caucasian comfrey species (S. asperum, S. caucasicum). Contrary to polysaccharides this phenolic polymer of Comfrey appeared to have a high immunomodulatory (anticomplement), antioxidative, antilipoperoxidantive, anti-inflammatory and wound-healing efficacy/activities. The aim of the study was development of the composition and technology of PDGA-containing gel. According to the results of complex biopharmaceutical studies PDGA gel optimal composition has been proved. The technological scheme for preparation of PDGA gel has been developed. PDGA gel stability under normal conditions of storage at +40С was studied. The gel has a shelf life (determined expiration date) of 2 year.
[Mh] Termos MeSH primário: Ácidos Glicéricos/química
[Mh] Termos MeSH secundário: Confrei/química
Liberação Controlada de Fármacos
Excipientes
Géis
Ácidos Glicéricos/isolamento & purificação
Osmose
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Gels); 0 (Glyceric Acids); 0 (poly(3-(3,4-dihydroxyphenyl)glyceric acid))
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170303
[St] Status:MEDLINE


  7 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28076845
[Au] Autor:Wang Y; Cai WS; Chen L; Wang G
[Ad] Endereço:Department of Biology, Southern University of Science and Technology, Shenzhen 518055, China.
[Ti] Título:Molecular dynamics simulation reveals how phosphorylation of tyrosine 26 of phosphoglycerate mutase 1 upregulates glycolysis and promotes tumor growth.
[So] Source:Oncotarget;8(7):12093-12107, 2017 Feb 14.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Phosphoglycerate mutase 1 (PGAM1) catalyzes the eighth step of glycolysis and is often found upregulated in cancer cells. To test the hypothesis that the phosphorylation of tyrosine 26 residue of PGAM1 greatly enhances its activity, we performed both conventional and steered molecular dynamics simulations on the binding and unbinding of PGAM1 to its substrates, with tyrosine 26 either phosphorylated or not. We analyzed the simulated data in terms of structural stability, hydrogen bond formation, binding free energy, etc. We found that tyrosine 26 phosphorylation enhances the binding of PGAM1 to its substrates through generating electrostatic environment and structural features that are advantageous to the binding. Our results may provide valuable insights into computer-aided design of drugs that specifically target cancer cells with PGAM1 tyrosine 26 phosphorylated.
[Mh] Termos MeSH primário: Glicólise
Simulação de Dinâmica Molecular
Fosfoglicerato Mutase/metabolismo
Tirosina/metabolismo
[Mh] Termos MeSH secundário: 2,3-Difosfoglicerato/química
2,3-Difosfoglicerato/metabolismo
Algoritmos
Sequência de Aminoácidos
Ácidos Glicéricos/química
Ácidos Glicéricos/metabolismo
Seres Humanos
Ligações de Hidrogênio
Neoplasias/genética
Neoplasias/metabolismo
Neoplasias/patologia
Fosfoglicerato Mutase/química
Fosfoglicerato Mutase/genética
Fosforilação
Análise de Componente Principal
Ligação Proteica
Homologia de Sequência de Aminoácidos
Eletricidade Estática
Especificidade por Substrato
Termodinâmica
Tirosina/química
Tirosina/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glyceric Acids); 138-81-8 (2,3-Diphosphoglycerate); 2553-59-5 (2-phosphoglycerate); 42HK56048U (Tyrosine); 820-11-1 (3-phosphoglycerate); EC 5.4.2.1 (phosphoglycerate mutase 1, human); EC 5.4.2.11 (Phosphoglycerate Mutase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170811
[Lr] Data última revisão:
170811
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170112
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.14517


  8 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27742850
[Au] Autor:Richard E; Blouin JM; Harambat J; Llanas B; Bouchet S; Acquaviva C; de la Faille R
[Ad] Endereço:1 Biothérapies des Maladies Génétiques, Inflammatoires et Cancers, Université de Bordeaux, Bordeaux, France.
[Ti] Título:Late diagnosis of primary hyperoxaluria type III.
[So] Source:Ann Clin Biochem;54(3):406-411, 2017 May.
[Is] ISSN:1758-1001
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We report the case of a 78-year-old patient with late diagnosis of hyperoxaluria type III (PH3). He developed renal failure after nephrectomy for clear cell papillary renal carcinoma and complained of recurrent urolithiasis for some 30 years, whose aetiology was never identified. Biochemical laboratory investigations of urine and urolithiasis composition revealed marked hyperoxaluria but normal concentrations of urinary glyceric and glycolic acid as well as stones of idiopathic calcium-oxalate appearance. Furthermore, the dietary survey showed excessive consumption of food supplements containing massive amounts of oxalate precursors. However, the persistence of excessive hyperoxaluria after his eating habits was changed leading us to perform molecular genetic testing. We found heterozygous mutations of the recently PH3-associated HOGA1 gene when sequencing PH genes. This is the first description of late diagnosis primary PH3 in a patient with several additional pro-lithogenic factors. This case illustrates the importance of undertaking a complete biological work-up to determine the aetiology of hyperoxaluria. This may reveal underdiagnosed primary hyperoxaluria, even in older patients.
[Mh] Termos MeSH primário: Diagnóstico Tardio
Hiperoxalúria Primária/diagnóstico
Mutação
Oxo-Ácido-Liases/genética
Urolitíase/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Carcinoma de Células Renais/diagnóstico
Carcinoma de Células Renais/patologia
Carcinoma de Células Renais/cirurgia
Expressão Gênica
Ácidos Glicéricos/urina
Glicolatos/urina
Seres Humanos
Hiperoxalúria Primária/complicações
Hiperoxalúria Primária/genética
Hiperoxalúria Primária/urina
Rim/metabolismo
Rim/patologia
Rim/cirurgia
Neoplasias Renais/diagnóstico
Neoplasias Renais/patologia
Neoplasias Renais/cirurgia
Masculino
Nefrectomia
Oxo-Ácido-Liases/metabolismo
Urolitíase/complicações
Urolitíase/genética
Urolitíase/urina
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glyceric Acids); 0 (Glycolates); 0WT12SX38S (glycolic acid); 70KH64UX7G (glyceric acid); EC 4.1.3.- (Oxo-Acid-Lyases); EC 4.1.3.16 (4-hydroxy-2-oxoglutarate aldolase)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161016
[St] Status:MEDLINE
[do] DOI:10.1177/0004563216677101


  9 / 973 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27502056
[Au] Autor:Ferreira C; Soares AR; Lamosa P; Santos MA; da Costa MS
[Ad] Endereço:Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504, Coimbra, Portugal.
[Ti] Título:Comparison of the compatible solute pool of two slightly halophilic planctomycetes species, Gimesia maris and Rubinisphaera brasiliensis.
[So] Source:Extremophiles;20(6):811-820, 2016 Nov.
[Is] ISSN:1433-4909
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Gimesia maris and Rubinisphaera brasiliensis are slightly halophilic representatives of the deep-branching phylum Planctomycetes. For osmoadaptation both species accumulated α-glutamate, sucrose, ectoine and hydroxyectoine. A major role was found for ectoine, hydroxyectoine as well as sucrose under hyper-osmotic shock conditions. Nevertheless, the levels of sucrose were up-regulated by the increased salinity levels and also by low nitrogen availability. Additionally, G. maris accumulated glucosylglycerate (GG) as major solute specifically under low nitrogen levels, which prompted us to analyse the transcript abundance of two homologues genes known for the biosynthesis of GG, namely glucosyl-3-phosphoglycerate synthase (GpgS) and glucosyl-3-phosphoglycerate phosphatase (GpgP). By qPCR using a suitable reference gene selected in this study, the transcript abundance of the biosynthetic genes was quantified in G. maris cells under hyper-osmotic shock or under low nitrogen conditions. The gpgS gene was induced under nitrogen-limiting conditions suggesting that GG synthesis is regulated primarily at the transcription level. Moreover, the expression of a gene coding for a putative sucrose-phosphorylase (Spase) located upstream the gpgS and gpgP genes was up-regulated, predicting a metabolic role of Spase probably related to GG synthesis.
[Mh] Termos MeSH primário: Bactérias/genética
Glucosídeos/metabolismo
Ácidos Glicéricos/metabolismo
Pressão Osmótica
Tolerância a Sal
[Mh] Termos MeSH secundário: Bactérias/enzimologia
Bactérias/metabolismo
Proteínas de Bactérias/genética
Proteínas de Bactérias/metabolismo
Glucosiltransferases/genética
Glucosiltransferases/metabolismo
Nitrogênio/metabolismo
Monoéster Fosfórico Hidrolases/genética
Monoéster Fosfórico Hidrolases/metabolismo
Plâncton/enzimologia
Plâncton/genética
Plâncton/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (2-glucosylglycerate); 0 (Bacterial Proteins); 0 (Glucosides); 0 (Glyceric Acids); EC 2.4.1.- (Glucosyltransferases); EC 3.1.3.2 (Phosphoric Monoester Hydrolases); N762921K75 (Nitrogen)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:160810
[St] Status:MEDLINE


  10 / 973 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27071404
[Au] Autor:Jorge CD; Borges N; Bagyan I; Bilstein A; Santos H
[Ad] Endereço:Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República-EAN, 2780-157, Oeiras, Portugal. cjorge@itqb.unl.pt.
[Ti] Título:Potential applications of stress solutes from extremophiles in protein folding diseases and healthcare.
[So] Source:Extremophiles;20(3):251-9, 2016 May.
[Is] ISSN:1433-4909
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Protein misfolding, aggregation and deposition in the brain, in the form of amyloid, are implicated in the etiology of several neurodegenerative disorders, such as Alzheimer's, Parkinson's and prion diseases. Drugs available on the market reduce the symptoms, but they are not a cure. Therefore, it is urgent to identify promising targets and develop effective drugs. Preservation of protein native conformation and/or inhibition of protein aggregation seem pertinent targets for drug development. Several studies have shown that organic solutes, produced by extremophilic microorganisms in response to osmotic and/or heat stress, prevent denaturation and aggregation of model proteins. Among these stress solutes, mannosylglycerate, mannosylglyceramide, di-myo-inositol phosphate, diglycerol phosphate and ectoine are effective in preventing amyloid formation by Alzheimer's Aß peptide and/or α-synuclein in vitro. Moreover, mannosylglycerate is a potent inhibitor of Aß and α-synuclein aggregation in living cells, and mannosylglyceramide and ectoine inhibit aggregation and reduce prion peptide-induced toxicity in human cells. This review focuses on the efficacy of stress solutes from hyper/thermophiles and ectoines to prevent amyloid formation in vitro and in vivo and their potential application in drug development against protein misfolding diseases. Current and envisaged applications of these extremolytes in neurodegenerative diseases and healthcare will also be addressed.
[Mh] Termos MeSH primário: Diamino Aminoácidos/farmacologia
Amiloide/efeitos dos fármacos
Archaea/metabolismo
Bactérias/metabolismo
Ácidos Glicéricos/farmacologia
Glicerofosfatos/farmacologia
Manose/análogos & derivados
Deficiências na Proteostase/prevenção & controle
Estresse Fisiológico
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Manose/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Amino Acids, Diamino); 0 (Amyloid); 0 (Glyceric Acids); 0 (Glycerophosphates); 0 (diglycerol phosphate); 0 (mannosylglycerate); 7GXZ3858RY (ectoine); PHA4727WTP (Mannose)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:160414
[St] Status:MEDLINE
[do] DOI:10.1007/s00792-016-0828-8



página 1 de 98 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde